8-K: Cerus Corporation Announces Positive Topline Results for Phase 3 Trial of INTERCEPT Blood System for Red Blood Cells

Cerus Corporation's Phase 3 clinical trial for its INTERCEPT Blood System for Red Blood Cells met its primary efficacy endpoint, demonstrating non-inferiority compared to conventional red blood cells in cardiovascular surgery patients.

Summary

• Cerus Corporation announced positive topline results from its ReCePI Phase 3 clinical trial for the INTERCEPT Blood System for Red Blood Cells.
• The trial focused on patients undergoing complex cardiac surgery and evaluated the incidence of acute kidney injury (AKI) following transfusion.
• The study demonstrated that INTERCEPT RBCs were non-inferior to conventional RBCs in terms of AKI incidence, with 29.3% of INTERCEPT RBC recipients experiencing AKI compared to 28.0% of conventional RBC recipients.
• The upper limit of the 95% confidence interval was 10.4%, which was less than the non-inferiority margin of 14.0% (p = 0.001).
• The safety endpoint, measured by treatment-emergent adverse events, was not significantly different between the two groups, with 2.5% for INTERCEPT RBCs and 0.6% for conventional RBCs (p = 0.130).
• There were no clinically significant treatment-emergent RBC antibodies observed in five patients receiving INTERCEPT RBCs.
• Cerus plans to submit a modular premarket approval (PMA) application to the FDA in the second half of 2025, with the final module submission expected in the second half of 2026.
• The PMA submission will include data from the ReCePI and RedeS clinical trials, as well as other relevant data.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the successful trial results and progress towards regulatory approval. However, there are some risks and uncertainties associated with the regulatory process and future trials.

Positives

• The trial successfully met its primary efficacy endpoint, demonstrating non-inferiority of INTERCEPT RBCs compared to conventional RBCs.
• The safety profile of INTERCEPT RBCs was comparable to conventional RBCs, with no significant difference in adverse events.
• The absence of clinically significant treatment-emergent RBC antibodies is a positive safety finding.
• The company is progressing towards a PMA submission to the FDA, with a modular approach planned for the second half of 2025.
• The successful trial results bring Cerus closer to potentially making pathogen reduction available for red blood cells, the most commonly transfused blood component.

Negatives

• The safety endpoint, while not significantly different, did show a higher percentage of treatment-emergent adverse events in the INTERCEPT RBC group (2.5%) compared to the conventional RBC group (0.6%).
• The PMA submission is not expected until the second half of 2025, with final submission in the second half of 2026, indicating a lengthy regulatory process.

Risks

• The topline results are subject to change following a more comprehensive review of the data.
• The PMA submission may be delayed or may not occur due to various reasons, including those outside of Cerus' control.
• The company may be unable to report data from its RedeS clinical trial in a timely manner or at all, and the data may not support the PMA submission.
• The FDA may not accept the PMA submission for review or may not approve it in a timely manner.
• There are risks related to product safety, including the occurrence of antibody reactivity to INTERCEPT RBCs.
• The company's supply chain could be negatively impacted by macroeconomic developments, including military conflicts and the COVID-19 pandemic.
• Cerus may be unable to demonstrate to the transfusion medicine community that pathogen reduction is safe, effective, and economical.
• The company may need additional funding.

Future Outlook

Cerus anticipates initiating a modular PMA application to the FDA in the second half of 2025, with the final PMA module submission planned for the second half of 2026, upon the anticipated completion of the RedeS clinical trial. The company also expects to present the data from the ReCePI clinical trial at upcoming medical conferences and submit it for peer-reviewed publication.

Management Comments

• Richard Benjamin, M.D., Ph.D., Cerus chief medical officer, stated that the ReCePI clinical trial is a pioneering trial in the field of transfusion medicine.
• William Obi Greenman, Cerus president and chief executive officer, stated that the results are an important milestone for the INTERCEPT RBC program and bring the company closer to making pathogen reduction available for RBCs.

Industry Context

This announcement is significant for the blood transfusion industry as it represents a step forward in making pathogen reduction technology available for red blood cells, which are the most commonly transfused blood component. This could potentially improve blood safety and reduce the risk of transfusion-transmitted infections.

Comparison to Industry Standards

• The trial's non-inferiority design is consistent with regulatory standards for evaluating new medical devices and treatments.
• The use of acute kidney injury (AKI) as a primary endpoint is a relevant and sensitive indicator of RBC tissue oxygen delivery, aligning with industry best practices.
• The trial's methodology, including randomization and blinding, is in line with high-quality clinical research standards.
• The results will be compared to other pathogen reduction technologies and transfusion practices in the industry, such as those used by Terumo BCT and Macopharma, to assess the relative benefits and risks of the INTERCEPT system.

Stakeholder Impact

• Shareholders will likely react positively to the successful trial results and progress towards regulatory approval.
• Patients may benefit from the availability of pathogen-reduced red blood cells, potentially reducing the risk of transfusion-transmitted infections.
• Blood centers may adopt the INTERCEPT system if it receives regulatory approval, potentially improving the safety of the blood supply.
• Clinicians will have access to a new technology that could improve patient outcomes.

Next Steps

• Cerus will complete the RedeS Phase 3 clinical trial for INTERCEPT RBCs.
• The company will prepare and submit a modular PMA application to the FDA in the second half of 2025.
• Cerus will present the ReCePI trial data at medical conferences and submit it for peer-reviewed publication.

Key Dates

Keywords

INTERCEPT Blood System, Red Blood Cells, Pathogen Reduction, Clinical Trial, Acute Kidney Injury, Transfusion, PMA, FDA, Cardiovascular Surgery, Blood Safety